The Cold Open
Melanotan II started as a skin-cancer prevention project. University of Arizona researchers wanted a drug that would darken skin without UV exposure. It worked. Skin tanned on schedule. Along the way, they discovered something unexpected: it also triggered spontaneous erections. That accidental finding eventually led to the first FDA-approved melanocortin drug. Melanotan II itself is still not approved, still sold online, and still showing up in emergency rooms. This month: what it does and what happens when regulation is skipped.
Peptide of the Month: Melanotan II
What it is. MT-II is a cyclic seven-amino-acid synthetic analog of alpha-MSH, the hormone your body uses to tell skin cells to make pigment. MT-II binds the same receptors, but hits several at once (MC1R, MC3R, MC4R, MC5R). MC1R in the skin triggers tanning. MC4R in the brain triggers appetite suppression and sexual arousal. MT-II is a master key that opens four different locks simultaneously.
What it's supposedly for. Tanning without sun exposure, erectile dysfunction, appetite suppression, libido. Heavily marketed in bodybuilding, beach, and biohacker communities. Sold as injectable powder.
The evidence as of today. The early trials were real. A 1996 Phase I study showed MT-II induced skin pigmentation, with nausea and unexpected erections as common side effects. Two Phase II trials in 1998 and 2000 tested it in men with psychogenic and organic erectile dysfunction. Results were striking: in the psychogenic cohort, 8 of 10 men got clinically meaningful erections with a mean duration of 38 minutes, versus 3 minutes on placebo. A 2000 organic-ED study reported erections in 12 of 19 active doses and 1 of 21 placebo doses.
One thing to know: its child is FDA-approved. The MT-II development program was halted because of side effects: nausea, cardiovascular strain, spontaneous erections, uncontrolled pigmentation. Researchers then isolated an active metabolite of MT-II and made Bremelanotide, also called PT-141. That compound got FDA approval as Vyleesi in 2019. MT-II is the parent that didn't make it through the clinic. Its descendant did.
Melanotan II works. That's the problem. It works at too many receptors, too strongly, with too many side effects to be a drug.
The catch. MT-II is not FDA-approved and never will be. Case reports in medical journals document rhabdomyolysis (muscle breakdown that can destroy kidneys), hypertensive crises, eruptive atypical moles, and at least one report of melanoma in long-term users. The grey-market vials are often impure. Dosing is eyeballed. This is the single peptide in this newsletter with the most documented acute harm.
Skeptic's Corner: The grey market is not the research literature
Fans will point to the Phase II data and say "it's studied, it's validated." And those trials are real.
Here's the gap. Trial-grade MT-II was synthesized and purified under controlled conditions, dosed at 0.025 mg/kg, and administered once in a monitored clinic. Grey-market MT-II is lyophilized powder from a research-chemical vendor, reconstituted at home, dosed by visual estimate, taken daily for weeks. The molecule in a Phase II trial and the substance in a kitchen drawer can be the same peptide or wildly different ones.
The rule: The results of a clinical trial belong to the molecule in that trial. Transferring them to a vial off the internet is an assumption, not a conclusion.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.